What have we learned?

As we move deeper into earnings season it’s a good time to reflect on what we have learned so far. One thing we are definitely learning is that the FDA excuse the expression is taking their sweet time in approving the Libre2 and Control IQ. We have no doubt that both approvals are coming just when is another matter. Based on all the available information we have the Control IQ approval should come soon while the Libre2 seems destine to be pushed into the first quarter of next year.

We’re also learning that when it comes to diabetes . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.